Sunshine Biopharma, Inc.

NasdaqCM:SBFM Stock Report

Market Cap: US$3.4m

Sunshine Biopharma Management

Management criteria checks 4/4

Sunshine Biopharma's CEO is Steve Slilaty, appointed in Oct 2009, has a tenure of 16.75 years. total yearly compensation is $545.95K, comprised of 85.3% salary and 14.7% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $12.62. The average tenure of the management team and the board of directors is 9.6 years and 4.4 years respectively.

Key information

Steve Slilaty

Chief executive officer

US$546.0k

Total compensation

CEO salary percentage85.35%
CEO tenure16.8yrs
CEO ownership0.0004%
Management average tenure9.6yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Analysis Article • Mar 14

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Jan 29

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

With a price-to-sales (or "P/S") ratio of 0.3x Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) may be sending very bullish...
Analysis Article • Sep 12

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) share price has dived 26% in the last...
Seeking Alpha • Oct 20

Sunshine Biopharma acquires Nora Pharma for C$30M

Sunshine Biopharma (NASDAQ:SBFM) said on Thursday it had completed the acquisition of all the outstanding shares of Nora Pharma for C$30M ($21.9M). The acquisition will help Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. Nora Pharma currently offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma will operate as a subsidiary of Sunshine. (SBFM) is down ~4% premarket.
Analysis Article • Aug 08

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 04

Sunshine Biopharma reports 1H results

Sunshine Biopharma press release (NASDAQ:SBFM): 1H Revenue of $0.27M. The Company had a net loss of $1,775,106 in the first half of 2022, compared to a net loss of $9,064,180 in the first half of 2021.
Seeking Alpha • Apr 17

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Sunshine Biopharma is developing novel Topoisomerase II inhibiting cancer therapies and PLpro inhibiting antiviral drugs. The Company has a strong IP backing, although much of it is tied in with the CEO. The Company recently raised $13.6 million in net proceeds from a public offering following a 200:1 reverse split, and a private placement. Note: we do not recommend stocks with such low market caps however attractive they may otherwise sound.

CEO Compensation Analysis

How has Steve Slilaty's remuneration changed compared to Sunshine Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$6m

Dec 31 2025US$546kUS$466k

-US$6m

Sep 30 2025n/an/a

-US$6m

Jun 30 2025n/an/a

-US$6m

Mar 31 2025n/an/a

-US$5m

Dec 31 2024US$1mUS$412k

-US$5m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$640kUS$378k

-US$5m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$430kUS$360k

-US$27m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$462kUS$156k

-US$12m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$227kUS$177k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$972k

Dec 31 2019US$96kUS$28k

-US$1m

Compensation vs Market: Steve's total compensation ($USD545.95K) is about average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Slilaty (74 yo)

16.8yrs
Tenure
US$545,953
Compensation

Dr. Steve N. Slilaty, Ph.D. is CEO & Chairman of Sunshine Biopharma, Inc. from October 15, 2009 and serves as its President. Dr. Slilaty joined the Sunshine Biopharma, Inc. on October 15, 2009. He serves a...

Leadership Team

NamePositionTenureCompensationOwnership
Steve Slilaty
Chairman16.8yrsUS$545.95k0.00037%
$ 12.6
Camille Sebaaly
CFO, Secretary & Director16.8yrsUS$412.28k0.00037%
$ 12.6
Michel Roy
Chief Commercial Officer1.5yrsUS$283.17k0.000060%
$ 2.0
Malek Chamoun
Chief Development Officer2.5yrsno data0.011%
$ 390.2
Robert Ferreira
President of Sunshine Bio Investments Incno datano datano data
9.6yrs
Average Tenure
64yo
Average Age

Experienced Management: SBFM's management team is seasoned and experienced (9.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steve Slilaty
Chairman16.8yrsUS$545.95k0.00037%
$ 12.6
Camille Sebaaly
CFO, Secretary & Directorless than a yearUS$412.28k0.00037%
$ 12.6
David Natan
Independent Director4.4yrsUS$80.00k0.62%
$ 21.1k
Rabi Kiderchah
Independent Director4.8yrsUS$80.00k0.000060%
$ 2.0
Andrew Keller
Independent Director4.4yrsUS$80.00kno data
4.4yrs
Average Tenure
72yo
Average Age

Experienced Board: SBFM's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 09:48
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sunshine Biopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation